Please use this identifier to cite or link to this item:
https://open.uns.ac.rs/handle/123456789/1036
Title: | Incidence and predictors of bleeding in ACS patients treated with PCI and prasugrel or ticagrelor: An analysis from the RENAMI registry | Authors: | D'Ascenzo F. Grosso A. Abu-Assi E. Kinnaird T. Ariza-Solé A. Manzano-Fernández S. Templin C. Lazar Velicki Xanthopoulou I. Cerrato E. Rognoni A. Boccuzzi G. Omedè P. Montabone A. Taha S. Durante A. Gili S. Ali H. Magnani G. Autelli M. Blanco P. Garay A. Quadri G. Marra W. Varbella F. Queija B. Paz R. Fernández M. Pousa I. Gallo D. Morbiducci U. Dominguez-Rodriguez A. Valdés M. Cequier A. Alexopoulos D. Iñiguez-Romo A. Gaita F. Raposeiras-Roubin S. |
Keywords: | Acute coronary syndrome;Percutaneous coronary intervention;Dual antiplatelet therapy;Prasugrel;Ticagrelor;Major bleeding | Issue Date: | 15-Dec-2018 | Journal: | International Journal of Cardiology | Abstract: | © 2018 Elsevier B.V. Objectives: To evaluate “real life” incidence and independent predictors of major bleeding defined in ACS patients treated with PCI and current standard antithrombotic therapy with prasugrel or ticagrelor. Methods and results: The RENAMI project is a multicenter retrospective observational registry enrolling 4424 patients with ACS treated with PCI and prasugrel or ticagrelor plus aspirin. Primary endpoint was MACE (major adverse cardiovascular events). Secondary endpoints included each component of MACE, cardiovascular death (CV death), recurrence of ACS (reACS) and stroke. Eighty three (1.8%) patients developed out of hospital major bleedings after 14.1 ± 6.2 months. These patients had higher rates of MACE (14.5% vs 4.4%; p = 0.001) and of all-cause death (11% vs 2.1%; p < 0.001). Independent predictors of major bleeding were age >75 years (OR 2.00; 95% CI 1.18–3.41; p = 0.010) and female sex (OR 1.66; 95% CI 1.02–2.70; p = 0.041). BARC 3–5 bleeding was independently associated with all-cause mortality (OR 3.46; 95% CI 1.64–7.31; p 0.001). Conclusion: In ACS patients treated with PCI and ticagrelor or prasugrel, BARC 3–5 bleedings despite being uncommon negatively impacted on prognosis. Old and female patients are at increased risk, offering clinical indications for tailoring dual antiplatelet therapy. | URI: | https://open.uns.ac.rs/handle/123456789/1036 | ISSN: | 1675273 | DOI: | 10.1016/j.ijcard.2018.09.020 |
Appears in Collections: | MDF Publikacije/Publications |
Show full item record
SCOPUSTM
Citations
14
checked on May 10, 2024
Page view(s)
33
Last Week
10
10
Last month
0
0
checked on May 10, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.